GlobeNewswire by notified

Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible

Share

Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules.

Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors.

Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality.

The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, including food, cosmetic, personal care, pharmaceutical and medical. In industrial applications, such as anti-fouling paint for boats and ships, capsaicin has the potential to replace heavy metals.

“The successful scale-up of our fermentation process for capsaicinoids is a good example of Conagen’s innovative advancements in gene discovery, strain engineering and process development and optimization,” said Dr. Casey Lippmeier, vice president of innovation at Conagen. “The complimentary addition of capsaicinoids to our product portfolio enhances our motivation to meet consumers’ demand for sustainable, nature-based, and clean ingredients.”

Two major capsaicinoids, capsaicin and dihydrocapsaicin are responsible for roughly up to 90% of the pungency in chili pepper.

Yet, another capsaicinoid, nonivamide, also known as Pelargonic Acid Vanillylamide, (PAVA) is found in small, trace amounts in hot peppers. It is an alternative to capsaicin for its hot sensation and spicy flavoring. Nonivamide is typically used in topical muscle pain relievers and synthetic pepper spray, respectfully.

Due to the extremely low content of nonivamide in hot peppers, and the large demand, current plant extraction methods are not commercially viable. Thus, nonivamide has exclusively been made by chemical synthesis. Although chemically synthesized nonivamide is readily available, consumers are adopting clean and natural products.

Providing a solution to global capsaicin shortages, Conagen has identified several key genes in the capsaicin biosynthetic pathway in hot peppers and has demonstrated proof-of-concepts for the production of capsaicin, dihydrocapsaicin, and nonivamide. Several patents have been granted to Conagen for microbial production of capsaicinoids.

As a result of the demand for a natural, low cost-in-use solution, Conagen has successfully optimized and scaled-up its fermentation process for the production of capsaicin, dihydrocapsaicin, and nonivamide.

###

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop sustainable, nature-based molecules bio-manufactured into the highest quality products available. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares24.4.2024 03:36:40 CEST | Press release

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions. Goldman Sachs, Leerink Partners, Eve

UK businesses must prioritise payment technology to build customer loyalty and stay competitive: New research from Lloyds Bank and FreedomPay24.4.2024 01:01:00 CEST | Press release

London, United Kingdom, April 23, 2024 (GLOBE NEWSWIRE) -- Less than a third (27%) of businesses are confident they offer seamless payments experiences.Almost two-thirds of businesses (59%) across Retail, Food & Beverages and Hospitality believe a good checkout experience offers the same competitive advantage as having the best products.Customer preference is the factor most likely to influence businesses’ investment in payment technologies. New research from Lloyds Bank and FreedomPay highlights the importance of UK businesses investing in new payment technology. Two-thirds (59%) of UK Retail, Food & Beverage (F&B) and Hospitality companies were found to already put payments at the heart of their customer experience strategy, reflecting the growing importance of payment options to customers. For retail-focused businesses, 59% believe that a good checkout experience is essential to building customer loyalty, with respondents believing it is as much a competitive advantage as having the

Millicom announces the re-issuance of its AGM and EGM Convening Notice23.4.2024 22:30:00 CEST | Press release

Millicom announces the re-issuance of its AGM and EGM Convening Notice Luxembourg, April 23, 2024 – Millicom today announced the re-issuance of the Convening Notice to its Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) of Shareholders which will be held on May 23, 2024. The Convening Notice contains a rectified note to the AGM agenda item 20 (Share Repurchase Plan). All other items of the AGM and EGM remain unchanged. The Convening Notice is appended to this press release and available on the company’s website at: https://www.millicom.com/our-company/corporate-governance/shareholder-meetings/. AGM voting materials have been updated to reflect the rectified note. -END- For further information, please contact AGM/EGM Inquiries: Patrick Gill, Company Secretary +352 27 759 603 Maria Florencia Maiori, Senior Legal Counsel information@millicom.comPress: Sofia Corral, Director Corporate Communications press@millicom.comInvestors: Michel Morin, VP Investor Relations i

CNH announces signing of a €3.25 billion committed revolving credit facility23.4.2024 22:30:00 CEST | Press release

CNH announces signing of a €3.25 billion committed revolving credit facility Basildon, April 23, 2024 On April 19, 2024, CNH (NYSE: CNHI) signed a €3.25 billion committed revolving credit facility, intended for general corporate purposes of the Company. The facility, entered into with a group of 18 banks providing aggregate commitments in excess of €3.5 billion, has a 5-year tenor with two extension options of one year each, exercisable on the first and second anniversary of the signing date. It replaces an existing 5-year €4 billion facility due to mature in March 2026. The final size of the facility, set at €3.25 billion, aligns with reduced funding needs following the demerger of Iveco Group. The transaction confirms the strong support of a large panel of international key relationship banks for the Company. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Produc

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares23.4.2024 22:17:37 CEST | Press release

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running mana

HiddenA line styled icon from Orion Icon Library.Eye